Targeting Breast Cancer-Derived Stem Cells by Dietary Phytochemicals: A Strategy for Cancer Prevention and Treatment
No Thumbnail Available
Date
2022-06-10T00:00:00
Journal Title
Journal ISSN
Volume Title
Publisher
MDPI
Abstract
Breast cancer is heterogeneous disease with variable prognosis and therapeutic response. Approximately, 70% of diagnosed breast cancer represents the luminal A subtype. This subpopulation has a fair prognosis with a lower rate of relapse than the other clinical subtypes. Acquisition of stemness in luminal A subtype modifies the phenotype plasticity to accomplish increased aggressiveness and therapeutic resistance. Therefore, targeting luminal A-derived breast cancer stem cells (BCSCs) could be a promising strategy for its prevention and treatment. Extensive studies reveal that dietary phytochemicals have the potential to target BCSCs by modulating the molecular and signal transduction pathways. Dietary phytochemicals alone or in combination with standard therapeutic modalities exert higher efficacy in targeting BCSCs through changes in stemness, self-renewal properties and hypoxia-related factors. These combinations offer achieving higher radio-and chemo-sensitization through alteration in the key signaling pathways such as AMPK, STAT3, NF-kB, Hedgehog, PI3K/Akt/mTOR, Notch, GSK3?, and Wnt related to cancer stemness and drug resistance. In this review, we highlight the concept of targeting luminal A-derived BCSCs with dietary phytochemicals by summarizing the pathways and underlying mechanism(s) involved during therapeutic resistance. � 2022 by the authors. Licensee MDPI, Basel, Switzerland.
Description
Keywords
breast cancer stem cells, cancer prevention, dietary phytochemical, luminal A subtype, signaling pathway, therapeutic resistance